Top

Published in:

01-04-2013 | Brief Research Article

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients

Authors: Xu Liang, Jie Zhang, Yulin Zhu, Yuanli Lu, Xinna Zhou, Zheng Wang, Jing Yu, Ying Yan, Lijun Di, Li Che, Hanfang Jiang, Bin Shao, Xiaoli Wang, Huabing Yang, Herbert Kim Lyerly, Jun Ren

Published in: Clinical and Translational Oncology | Issue 4/2013

Abstract

Aim

This study was designed to explore the genetic polymorphism of IL-10 (−1082A/G, −592A/C, −819T/C), TNF-α (−308G/A) with susceptibility to docetaxel-induced liver injury (DILI) in Chinese breast cancer patients.

Methods

The targeted genetic polymorphisms of IL10-1082G/A, IL10-592A/C, IL10-819T/C, TNF-308G/A from 40 patients with DILI were assayed by matrix-assisted laser desorption/ionization-time of flight of Sequenom.

Results

AA genotype of IL10-592 and TT of IL10-819 significantly increased incidence of DILI (P = 0.005, OR = 3.137). No differences of TNF gene polymorphism between the two groups were seen.

Conclusion

The genetic polymorphism of the IL10-592A/C AA genotype and IL10-819T/C TT genotype was predominantly conferred to the incidence of docetaxel-induced liver injury.

Temple RJ, Himmel MH (2002) Safety of newly approved drugs: implications for prescribing. JAMA 287:2273–2275PubMedCrossRef

Wang Z, Liang X, Yu J et al (2012) Non-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients. J Gastroenterol Hepatol 27:1348–1352PubMedCrossRef

Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489–499PubMedCrossRef

Aithal GP, Ramsay L, Daly AK et al (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430–1440PubMedCrossRef

Wanidworanun C, Strober W (1993) Predominant role of tumor necrosis factor-alpha in human monocyte IL10 synthesis. J Immunol 151:6853–6861PubMed

D’Alfonso S, Richiardi PM (1994) A polymorphic variation in a putative regulation box of the TNF A promoter region. Immunogenetics 39:150–154PubMed

Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323–1330PubMedCrossRef

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215PubMedCrossRef

Ozer JS, Dieterle F, Troth S et al (2010) A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 28:486–494PubMedCrossRef

10.

Pulitano C, Sitia G, Aldrighetti L et al (2006) Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines. Hepatol Res 36:20–26PubMedCrossRef

11.

Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI (1995) Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 133:43–52PubMedCrossRef

12.

Pachkoria K, Lucena MI, Crespo E et al (2008) Analysis of IL10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49:107–114PubMedCrossRef

13.

Hoffmann SC, Stanley EM, Cox ED et al (2002) Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2:560–567PubMedCrossRef

14.

Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L (2008) Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet 35:197–205PubMedCrossRef

Title: Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients
Authors: Xu Liang
Jie Zhang
Yulin Zhu
Yuanli Lu
Xinna Zhou
Zheng Wang
Jing Yu
Ying Yan
Lijun Di
Li Che
Hanfang Jiang
Bin Shao
Xiaoli Wang
Huabing Yang
Herbert Kim Lyerly
Jun Ren
Publication date: 01-04-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 4/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0936-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer

Zoledronic acid and radiation: toxicity, synergy or radiosensitization?

VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers

Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

Impact of radiotherapy delay on survival in glioblastoma

Sacral chordoma: management of a rare disease in a tertiary hospital

Keynote webinar | Spotlight on antibody–drug conjugates in cancer